Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?

This article summarizes preclinical and clinical data on the efficacy and safety of two FGF21 agonist therapies in developmentExpert Opinion: Preclinical and clinical data justify further investigation of FGF21 agonist therapies for the treatment of NAFLD. However, issues including injection site reactions and possible effects on bone homeostasis means that safety must be evaluated carefully. PMID: 31948295 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31948295?dopt=Abstract

Source: Expert Opinion on Investigational Drugs - January 19, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research